A Randomized, Open-Label, Multicenter Phase III Study of SHR-A1811 for First-Line Treatment in Subjects With HER2-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer is a PHASE3 clinical asset sponsored by Jiangsu HengRui Medicine Co., Ltd. in Non-Small Cell Lung Cancer With HER2- Mutations. SEO and diligence focus: SHR-A1811, PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.